Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Complex Medical Dermatology Cases: Pearls and Pitfalls from Dermatomyositis
Description
The session discussed complex cases of dermatomyositis, emphasizing diagnostic approaches and treatment strategies. Key points included the importance of clinical correlations when interpreting skin biopsy results, as changes in the skin can mimic other conditions like lupus. The discussion covered diagnostic workups involving MRI, lab tests, and antibody panels, noting that positive ANA results are common but not definitive. Treatment protocols were outlined, starting with topical steroids for mild cases to systemic therapies like prednisone and immunosuppressants for moderate to severe cases. The importance of recognizing specific antibodies—TIF 1 gamma, MDA 5, and NXP 2—was highlighted, particularly regarding their associations with malignancies and disease severity. The session also underlined the significance of thorough malignancy screening tailored to individual risk profiles, especially for high-risk patients. Case studies were shared, illustrating common pitfalls in diagnosis and the utility of antibody testing. The importance of ongoing education and awareness in managing dermatomyositis to improve patient outcomes was emphasized, alongside notable advances in screening methodologies.
View moreConclusions
- The diagnosis of dermatomyositis can often be confirmed through specific myositis antibody panels.
- Clinical features and careful correlation with laboratory findings are critical in distinguishing dermatomyositis from other conditions like lupus.
- Extended myositis antibody profiles provide crucial prognostic information for individuals with dermatomyositis.
- Patients with TIF-1 gamma antibodies are at a higher risk of developing associated malignancies, particularly within three years following diagnosis.
- Anti-CCAR1 antibodies in TIF-1 gamma positive patients may indicate a lower risk of malignancy despite the association with TIF-1 gamma.
- MDA-5 antibodies are tied to rapidly progressive interstitial lung disease and myopathic forms of dermatomyositis.
- NXP2 antibodies have been linked to higher disease severity and calcinosis in dermatomyositis patients, as well as an increased risk of malignancy in adults.
- It is essential to implement malignancy screening protocols for dermatomyositis patients based on their risk stratification.
- Regular follow-up screenings for malignancy should be conducted for at least three years in high-risk patients with dermatomyositis.
- Mammen AL, Ann NY Acad Sci 2010; 1184:134-53
- Tartar DM et al, Clin Dermatol 2018; 36:508-524
- Callen JP, Wortmann RL, Clin Dermatol 2006; 24:363-73
- Fiorentino DF et al, J Am Acad Dermatol 2015; 72:449-55
- Targoff et al, Arthritis Rheum 2006; 54:3682-9
- Oldroyd A, et al, Rheumatology 2019; 58:650-655
- Bernet L et al, JAMA Dermatol 2016; 152; 1049-51
- Fiorentino D et al, J Clin Invest 2022; 132:e150201
- Fiorentino D et al, Arthritis Rheumatol 2023; 75:1238-1245
- Sato S, et al, Arth Rheum 2005; 52:1571-6
- Hamaguchi Y et al, Arch Dermatol 2011; 147:391-8
- Matsushita T et al, Br J Dermatol 2017; 176:395-402
- Fiorentino D et al, J Am Acad Dermatol 2011; 65:25-34
- Narang NS et al, Arth Car Res 2015; 67:667-672
- Valenzuela A et al, JAMA Dermatol 2014; 150:724-9
- Gunawardena H et al, Arth Rheum 2009; 1807-14
- Rogers A, et al, Arthritis Care Res 2017; 69:1909-1914
- Fiorentino DF et al, Arth Rheum 2013; 65:2954-62
- Oldroyd AGS, et al, Nat Rev Rheumatol 2023; 805-817